- Home
- CLDI vs KFFB Comparison
CLDI vs KFFB Comparison
Compare CLDI & KFFB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- KFFB
- Stock Information
- Founded
- CLDI 2014
- KFFB 2005
- Country
- CLDI United States
- KFFB United States
- Employees
- CLDI N/A
- KFFB N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- KFFB Savings Institutions
- Sector
- CLDI Health Care
- KFFB Finance
- Exchange
- CLDI Nasdaq
- KFFB Nasdaq
- Market Cap
- CLDI 14.0M
- KFFB N/A
- IPO Year
- CLDI N/A
- KFFB 2005
- Fundamental
- Price
- CLDI $0.48
- KFFB $2.58
- Analyst Decision
- CLDI Strong Buy
- KFFB
- Analyst Count
- CLDI 2
- KFFB 0
- Target Price
- CLDI $15.00
- KFFB N/A
- AVG Volume (30 Days)
- CLDI 387.2K
- KFFB 1.3K
- Earning Date
- CLDI 05-13-2025
- KFFB 05-09-2025
- Dividend Yield
- CLDI N/A
- KFFB N/A
- EPS Growth
- CLDI N/A
- KFFB N/A
- EPS
- CLDI N/A
- KFFB N/A
- Revenue
- CLDI N/A
- KFFB $7,987,000.00
- Revenue This Year
- CLDI N/A
- KFFB N/A
- Revenue Next Year
- CLDI N/A
- KFFB N/A
- P/E Ratio
- CLDI N/A
- KFFB N/A
- Revenue Growth
- CLDI N/A
- KFFB 5.86
- 52 Week Low
- CLDI $0.35
- KFFB $2.50
- 52 Week High
- CLDI $4.90
- KFFB $3.90
- Technical
- Relative Strength Index (RSI)
- CLDI 39.49
- KFFB 26.55
- Support Level
- CLDI $0.41
- KFFB $2.58
- Resistance Level
- CLDI $0.52
- KFFB $2.62
- Average True Range (ATR)
- CLDI 0.07
- KFFB 0.03
- MACD
- CLDI 0.02
- KFFB -0.02
- Stochastic Oscillator
- CLDI 66.50
- KFFB 0.00
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.